Kira-Sophie Becher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kira-Sophie Becher has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anika Retterath
Institut für Pharmazeutische und Medizinische Chemie, PharmaCampus, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, D-48149 Münster, Germany
2 shared publications - Christian Nienberg
Institut für Pharmazeutische und Medizinische Chemie, PharmaCampus, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, D-48149 Münster, Germany
2 shared publications - Henning D. Mootz
Institute of Biochemistry, University of Münster, Münster, Germany
2 shared publications - Joachim Jose
University of Munster
2 shared publications - Thorsten Saenger
Westfälische Wilhelms-Universität, Institut für Pharmazeutische und Medizinische Chemie, PharmaCampus, Correnstr. 48, 48149 Münster, Germany
1 shared publication
Latest Publications
- Open Access
- 27 June 2016
- Published by MDPI AG in Pharmaceuticals
- Vol. 9 (3) , 36
Site-Specific Labeling of Protein Kinase CK2: Combining Surface Display and Click Chemistry for Drug Discovery Applications
Human CK2 is a heterotetrameric constitutively active serine/threonine protein kinase and is an emerging target in current anti-cancer drug discovery. The kinase is composed of two catalytic CK2α subunits and two regulatory CK2β subunits. In order to establish an assay to identify protein-protein-interaction inhibitors (PPI) of the CK2α/CK2β interface, a bioorthogonal click reaction was used to modify the protein kinase α-subunit with a fluorophore. By expanding the genetic code, the unnatural amino acid para azidophenylalanine (pAzF) could be incorporated into CK2α. Performing the SPAAC click reaction (Strain-Promoted Azide-Alkyne Cycloaddition) by the use of a dibenzylcyclooctyne-fluorophore (DBCO-fluorophore) led to a specifically labeled human protein kinase CK2α. This site-specific labeling does not impair the phosphorylation activity of CK2, which was evaluated by capillary electrophoresis. Furthermore a dissociation constant (KD) of 631 ± 86.2 nM was determined for the substrate αS1-casein towards CK2α. This labeling strategy was also applied to CK2β subunit on Escherichia coli, indicating the site-specific modifications of proteins on the bacterial cell surface when displayed by Autodisplay.
- 27 June 2016
- Published by MDPI AG in Pharmaceuticals
- Vol. 9 (3) , 36
Open AccessSite-Specific Labeling of Protein Kinase CK2: Combining Surface Display and Click Chemistry for Drug Discovery Applications
Human CK2 is a heterotetrameric constitutively active serine/threonine protein kinase and is an emerging target in current anti-cancer drug discovery. The kinase is composed of two catalytic CK2α subunits and two regulatory CK2β subunits. In order to establish an assay to identify protein-protein-interaction inhibitors (PPI) of the CK2α/CK2β interface, a bioorthogonal click reaction was used to modify the protein kinase α-subunit with a fluorophore. By expanding the genetic code, the unnatural amino acid para azidophenylalanine (pAzF) could be incorporated into CK2α. Performing the SPAAC click reaction (Strain-Promoted Azide-Alkyne Cycloaddition) by the use of a dibenzylcyclooctyne-fluorophore (DBCO-fluorophore) led to a specifically labeled human protein kinase CK2α. This site-specific labeling does not impair the phosphorylation activity of CK2, which was evaluated by capillary electrophoresis. Furthermore a dissociation constant (KD) of 631 ± 86.2 nM was determined for the substrate αS1-casein towards CK2α. This labeling strategy was also applied to CK2β subunit on Escherichia coli, indicating the site-specific modifications of proteins on the bacterial cell surface when displayed by Autodisplay.
- Open Access
- 2 November 2015
- Published by MDPI AG
Click chemistry for advanced drug discovery applications of human protein kinase CK2
Human CK2 is a heterotetrameric constitutively active serine / threonine protein kinase and plays an important role in current cancer research [1]. The kinase is composed of two catalytic CK2α subunits and two regulatory CK2β subunits. Most protein-protein interaction (PPI) studies or screening assays are based on fluorescence detection and require the labeling of the target enzyme by a fluorophore. Unfortunately, through labeling by commercial applications the catalytic subunit CK2α loses activity. Furthermore, the labeling ratio of the protein sample differs and is not exactly reproducible. The solution for this problem was a bioorthogonal click reaction of the protein kinase. By expanding the genetic code, the unnatural amino acid para‑acidophenylalanine (pAzF) could be incorporated into CK2 [2]. Performing the SPAAC click reaction (Strain-Promoted Alkyne-Azide Cycloaddition) by the use of DBCO 545 (dibenzylcyclooctyne‑fluor 545) led to a specifically labeled human protein kinase CK2 [3]. This site specific labeling does not impair the phosphorylation activity of the kinase, which was evaluated by capillary electrophoresis. The innovatively labeled kinase in combination with the Autodisplay technology could be a significant advancement for inhibitor screening assays by flow cytometry and for CK2α/CK2β interaction studies [4]. References: Trembley, J.H. et al.: Biofactors 2010, 36(3): 187-95. Chin, J.W. et al.: J. Am. Chem. Soc. 2002, 124(31): 9026-7. Mbua, N.E. et al.: Chembiochem. 2011, 12(12): 1912-21. Jose, J., Meyer, T.F.: Microbiol. Mol. Biol. Rev. 2007, 71(4): 600-19.
- 2 November 2015
- Published by MDPI AG
Open AccessClick chemistry for advanced drug discovery applications of human protein kinase CK2
Human CK2 is a heterotetrameric constitutively active serine / threonine protein kinase and plays an important role in current cancer research [1]. The kinase is composed of two catalytic CK2α subunits and two regulatory CK2β subunits. Most protein-protein interaction (PPI) studies or screening assays are based on fluorescence detection and require the labeling of the target enzyme by a fluorophore. Unfortunately, through labeling by commercial applications the catalytic subunit CK2α loses activity. Furthermore, the labeling ratio of the protein sample differs and is not exactly reproducible. The solution for this problem was a bioorthogonal click reaction of the protein kinase. By expanding the genetic code, the unnatural amino acid para‑acidophenylalanine (pAzF) could be incorporated into CK2 [2]. Performing the SPAAC click reaction (Strain-Promoted Alkyne-Azide Cycloaddition) by the use of DBCO 545 (dibenzylcyclooctyne‑fluor 545) led to a specifically labeled human protein kinase CK2 [3]. This site specific labeling does not impair the phosphorylation activity of the kinase, which was evaluated by capillary electrophoresis. The innovatively labeled kinase in combination with the Autodisplay technology could be a significant advancement for inhibitor screening assays by flow cytometry and for CK2α/CK2β interaction studies [4]. References: Trembley, J.H. et al.: Biofactors 2010, 36(3): 187-95. Chin, J.W. et al.: J. Am. Chem. Soc. 2002, 124(31): 9026-7. Mbua, N.E. et al.: Chembiochem. 2011, 12(12): 1912-21. Jose, J., Meyer, T.F.: Microbiol. Mol. Biol. Rev. 2007, 71(4): 600-19.